Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Cancer immune evasion, immunoediting and intratumour heterogeneity
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 6
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma
Faria Nusrat, Akshay Khanna, Aditi Jain, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 2103-2103
Open Access | Times Cited: 9
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
Jean–Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 7, pp. 853-864
Closed Access | Times Cited: 9
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 1
In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches
Amar Ajmal, Muhammad Danial, Maryam Zulfat, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 551-551
Open Access | Times Cited: 6
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Koushik Mondal, Mahesh Kumar Posa, Revathi P Shenoy, et al.
Cells (2024) Vol. 13, Iss. 14, pp. 1221-1221
Open Access | Times Cited: 6
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
Ramil Khusnutdinov
Reviews and Advances in Chemistry (2025)
Closed Access
Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma
Bach Ardalan, Aaron Ciner, Yasmine Baca, et al.
Clinical Cancer Research (2025)
Open Access
Assessment of the quality of life in metastatic colorectal cancer patients with KRAS gene mutant: a case-control study
Fahmideh Bagrezaei, Bahram Pourghassem Gargari, Reza Eghdam Zamiri, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer.
Sara Raji, Hamed Zaribafzadeh, Tyler Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Decoding pancreatic cancer: key risk factors across genetics and lifestyle
Rohit Sharma, Rashmi Ghosh, Sourabh Kumar, et al.
Expert Review of Molecular Diagnostics (2025), pp. 1-5
Closed Access
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 704-704
Open Access
Comprehensive Bioinformatics Analyses and Experimental Validation of the Cell Cycle Related Protein SAPCD2 as a New Biomarker and Potential Therapeutic Target in Pancreatic Cancer
Yuting Liu, Bo Li, Lingling Ke, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 2855-2877
Open Access
Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING Agonist Plus Mutant KRAS mRNA
Xiao Xu, Xiang Wang, Yu‐Pei Liao, et al.
ACS Nano (2025)
Closed Access
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Joyeeta Roy, Rima Mouawad, Armita Kyani, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Prognostic Significance of 18F-FDG PET/CT Radiomics in Patients With Resectable Pancreatic Ductal Adenocarcinoma Undergoing Curative Surgery
Jang Yoo, Seung Hyup Hyun, Jaeho Lee, et al.
Clinical Nuclear Medicine (2024) Vol. 49, Iss. 10, pp. 909-916
Closed Access | Times Cited: 2
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Baofa Yu, Shengwen Shao, Wenxue Ma
Cancer Letters (2024), pp. 217350-217350
Open Access | Times Cited: 2
Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer
XUAN WANG, Judith Breuer, Stephan Garbe, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6249-6249
Open Access | Times Cited: 1
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma
Mahmoud Yousef, Mark W. Hurd, Abdelrahman Yousef, et al.
The Oncologist (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors
Paul Johannet, Somer Abdelfattah, Callahan M. Wilde, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 32, pp. 3847-3857
Closed Access | Times Cited: 1
Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation
Vishali Moond, Bhumi Maniyar, Prateek S. Harne, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 5, pp. 1056-1073
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top